GlassScriptPhysician profile
Sunil Sarvaria
NPI 1497772198
$45,508.85
in general payments reported to CMS, 2019-2025
35 companies · $1,211 in 2025
The $1,211 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $6,931 · 2021: $11K · 2022: $8,963 · 2023: $1,460 · 2024: $671 · 2025: $1,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,281 · Education: $59.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,281.43 |
| Education | $59.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $40,561.08 | 2019-2025 | |
| Abbvie INC. | $2,402.13 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Genzyme Corporation | $318.02 | 2022-2025 | |
| Janssen Biotech, INC. | $275.96 | 2021-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $259.54 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $241.85 | 2019-2025 | Trulance |
| Janssen Scientific Affairs, LLC | $147.88 | 2022 | |
| Madrigal Pharmaceuticals | $141.15 | 2024-2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $102.04 | 2024-2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $91.32 | 2023 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $90.46 | 2023-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $88.22 | 2022-2023 | |
| Pfizer INC. | $71.48 | 2023-2025 | |
| Ardelyx, INC. | $69.15 | 2023-2025 | Ibsrela |
| Alcresta Therapeutics, INC. | $64.44 | 2023 | Relizorb |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $59.63 | 2025 | Wegovy |
| Ironwood Pharmaceuticals, INC | $50.53 | 2021-2022 | |
| Evoke Pharma, INC. | $49.66 | 2024 | |
| Celgene Corporation | $40.76 | 2022 | |
| Intercept Pharmaceuticals, INC. | $39.18 | 2024-2025 | |
| Redhill Biopharma INC. | $37.64 | 2021-2024 | Talicia |
| Merck Sharp & Dohme LLC | $35.18 | 2021-2022 | |
| Shionogi INC | $32.78 | 2019 | |
| Boston Scientific Corporation | $32.49 | 2023 | |
| Braintree Laboratories, INC. | $30.78 | 2023-2025 | Suflave |
| Lucid Diagnostics INC. | $23.49 | 2023 | |
| Medtronic, INC. | $21.74 | 2024 | Interstim |
| Daiichi Sankyo INC. | $21.42 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $18.24 | 2024 | Irrigation Tubing |
| Lilly USA, LLC | $17.04 | 2024 | Omvoh |
| Teva Pharmaceuticals USA, INC. | $16.43 | 2024 | |
| Amgen INC. | $15.93 | 2022 | |
| Fresenius Kabi USA, LLC | $15.61 | 2023 | |
| Sandoz INC. | $14.47 | 2023 | |
| Allergan, INC. | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Sarvaria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.